1-ethyl-4-(ethoxymethyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-ethyl-4-(ethoxymethyl)benzene
• 英文别名: ethyl-(4-ethyl-benzyl)-ether；1-Aethoxymethyl-4-aethyl-benzol；Aethyl-(4-aethyl-benzyl)-aether；1-(Ethoxymethyl)-4-ethylbenzene
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: MQCSGOABEWUYLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-(ethoxymethyl)benzene 、 alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 生成 对乙基苯甲酸 、 4-乙基苯甲酸乙酯
  参考文献：
  名称：

  The Use of Liquid Phase Oxidation for the Preparation of Nuclearly Substituted Styrenes. III. p-Vinylbenzyl Acetate

  摘要：

  DOI：

  10.1021/ja01200a017
• 作为产物：
  描述：

  4-ethylbenzaldehyde diethyl acetal 在 Bis(2,3,5,6-tetrafluorophenyl)-(2,3,6-trichlorophenyl)borane 、 氢气 作用下， 以 四氢呋喃 为溶剂， 55.0 ℃ 、2.0 MPa 条件下， 反应 12.0h， 以73%的产率得到1-ethyl-4-(ethoxymethyl)benzene
  参考文献：
  名称：

  沮丧路易斯对的自动串联催化还原醛和酮的醚化反应

  摘要：

  在本文中，我们报道了单个沮丧的路易斯对（FLP）催化剂可以促进醛和酮的还原醚化。该反应不需要外源酸催化剂，但是FLP对H 2，R-OH或H 2 O的联合作用以可逆的“开启”方式产生所需的布朗斯台德酸。该方法不仅是一种补充性的无金属还原醚化方法，而且还是醚类的利基方法，这种方法在合成上不方便，甚至很难通过其他合成方案进行操作。

  DOI：

  10.1002/anie.201700231

文献信息

• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0268878A2

  公开（公告）日：1988-06-01

  Disclosed herein are salicylic acid copolymers having a weight average molecular weight of 500 10,000 and obtained (a) by condensing salicylic acid (i) with a benzyl alcohol (ii) and/or benzyl ether (iii) or a benzyl halide (iv) in the presence of an acid catalyst or (b) by reacting a co-condensation resin of (i) and (ii) and/or (iii) with (iv) or (c) by reacting a co-condensation resin of (i) and (ii) and/or (iii) or (iv) with a styrene derivative in the presence of an acid catalyst; multivalent metal salts of the salicylic acid copolymers; color-developing agents comprising the multivalent metal salts; and color-developing sheets suited for pressure-sensitive copying paper and comprising the color-developing agents. Their production processes are also disclosed.

  本文公开了水杨酸共聚物，其重量平均分子量为 500 10、000 的水杨酸共聚物；(a)在酸催化剂存在下，将水杨酸(i)与苄醇(ii)和/或苄醚(iii)或苄基卤化物(iv)缩合而得，或(b)将(i)和(ii)和/或(iii)的共缩合树脂与(iv)反应而得，或(c)在酸催化剂存在下，将(i)和(ii)和/或(iii)或(iv)的共缩合树脂与苯乙烯衍生物反应而得；水杨酸共聚物的多价金属盐；由多价金属盐组成的显色剂；以及由显色剂组成的适用于压敏复印纸的显色薄片。此外，还公开了它们的生产工艺。
• Color-developing compositions and their use
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0523697A1

  公开（公告）日：1993-01-20

  A color-developing composition comprises a multivalent-metal-modified salicylic acid resin (Resin A) and a polycondensation resin (resin B) at a weight ratio of 90-30 to 10-70. Resin A is composed of 5-35 mole% of a structural unit (I) and 65-95 mole% of at least one structural unit (II) or 65-95 mole% of a coupled structural unit of at least one unit (II) and at least one unit (III) and has a weight-average molecular weight of 350-5,000. Resin B is composed of the unit (II) and/or the unit (III) and has a weight-average molecular weight of 350-5,000. wherein Z represents M/m, M being a metal ion of m valence and m being an integer; R₁ and R₂ represent H or a C₁₋₁₂ alkyl, aralkyl, aryl or cycloalkyl group; R₃ and R₆ represent H or a C₁₋₄ alkyl group; and R₄ and R₅ represent H or CH₃.

  一种显色组合物包括一种多价金属改性水杨酸树脂（树脂 A）和一种缩聚树脂（树脂 B），两者的重量比为 90-30 比 10-70。树脂 A 由 5-35 摩尔%的结构单元（I）和 65-95 摩尔%的至少一个结构单元（II）或 65-95 摩尔%的至少一个单元（II）和至少一个单元（III）的耦合结构单元组成，其重量平均分子量为 350-5000。树脂 B 由单元（II）和/或单元（III）组成，重量平均分子量为 350-5000。 其中 Z 代表 M/m，M 为 m 价金属离子，m 为整数；R₁ 和 R₂ 代表 H 或 C₁₋₁₂ 烷基、芳基、芳烷基或环烷基；R₃ 和 R₆ 代表 H 或 C₁₋₄ 烷基；以及 R₄ 和 R₅ 代表 H 或 CH₃。
• Benzolactam compounds as protein kinase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10457669B2

  公开（公告）日：2019-10-29

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  本发明提供了一种式 (0) 的化合物： 或其药学上可接受的盐、N-氧化物或同系物；其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N； R1 选自 -(Alk1)t-Cyc1；其中 t 为 0 或 1； 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个氟原子取代的 C1-3 烃基； R3 是氢或基团 L1-R7； R4 选自氢、甲氧基和任选被取代的 C1-3 烷基；以及 R4a 选自氢和 C1-3 烷基； 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义； 只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂，可用于治疗 ERK1/2 介导的疾病。因此，这些化合物可用于治疗，特别是治疗癌症。
• BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190047990A1

  公开（公告）日：2019-02-14

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—R z and N; R 1 is selected from: -(Alk 1 ) t -Cyc 1 ; wherein t is 0 or 1; Optionally substituted C 1-6 acyclic hydrocarbon groups R 2 is selected from hydrogen; halogen; and C 1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R 3 is hydrogen or a group L 1 -R 7 ; R 4 is selected from hydrogen; methoxy; and optionally substituted C 1-3 alkyl; and R 4a is selected from hydrogen and a C 1-3 alkyl group; wherein R z , Alk 1 , Cyc 1 , L 1 and R 7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.